(3S,4R,5S,6R)-2,6-二(羟基甲基)四氢吡喃-2,3,4,5-四醇 | 3019-74-7

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (3S,4R,5S,6R)-2,6-二(羟基甲基)四氢吡喃-2,3,4,5-四醇
• 中文别名: 景天[酮庚]糖
• 英文名称: sedoheptulose
• 英文别名: (3S,4R,5R,6R)-1,3,4,5,6,7-hexahydroxy-heptan-2-one；D-altro-heptulose；D-sedoheptulose；CHEBI: 16802；D-altro-[2]heptulose；D-altro-1,3,4,5,6,7-Hexahydroxy-heptan-2-on；(3S,4R,5R,6R)-1,3,4,5,6,7-hexahydroxyheptan-2-one
• CAS: 3019-74-7
• 化学式: C₇H₁₄O₇
• 分子量: 210.184
• InChiKey: HSNZZMHEPUFJNZ-SHUUEZRQSA-N

物化性质

• 熔点：
  249 °C
• 沸点：
  628.0±55.0 °C(Predicted)
• 密度：
  1.645±0.06 g/cm3(Predicted)
• 溶解度：
  Easily soluble (water), slightly soluble (ethanol)
• 碰撞截面：
  150.73 Ų [M+Na]+ [CCS Type: DT, Method: stepped-field]

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  138
• 氢给体数：
  6
• 氢受体数：
  7

安全信息

• 海关编码：
  2914400090

反应信息

• 作为反应物：
  描述：

  (3S,4R,5S,6R)-2,6-二(羟基甲基)四氢吡喃-2,3,4,5-四醇 在 盐酸 作用下， 生成 景天庚酮糖
  参考文献：
  名称：

  Sedoheptulose—Its Rotation, Reducing Power, Equilibrium with Sedoheptulosan in Acid Solution, and Crystalline Hexaacetate; Also Crystalline 2,7-Anhydro-β-D-altro-heptulofuranose

  摘要：

  DOI：

  10.1021/ja01599a050
• 作为产物：
  描述：

  D-altronic acid 生成 (3S,4R,5S,6R)-2,6-二(羟基甲基)四氢吡喃-2,3,4,5-四醇
  参考文献：
  名称：

  Synthesis of Sedoheptulose (D-Altroheptulose)¹

  摘要：

  DOI：

  10.1021/ja01129a014

文献信息

• Bna Conjugates and Methods of Use
  申请人：James Kenneth D.

  公开号：US20080207505A1

  公开（公告）日：2008-08-28

  Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, decreasing arterial blood pressure and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the hBNP compound are also disclosed, having an amino acid sequence that is other than the native sequence.

  本发明公开了改性利钠肽化合物及其共轭物。具体而言，提供了至少连接有一个修饰基团的hBNP的共轭形式。这些改性利钠肽化合物共轭物保留了刺激cGMP产生、结合NPR-A受体、降低动脉血压以及在某些实施例中相对于未经改性的对应利钠肽化合物具有改善的循环半衰期的活性。这些化合物和共轭物的口服、静脉注射、肠内、皮下、肺部和静脉形式可作为治疗和/或治疗心脏病症，特别是充血性心力衰竭的治疗。还公开了包含具有各种长度和构型的寡聚结构的修饰基团。此外，还公开了hBNP化合物的类似物，其氨基酸序列与天然序列不同。
• [EN] OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS<br/>[FR] COMPOSÉS D'OLIGOSACCHARIDE POUR UTILISATION DANS LA MOBILISATION DE CELLULES SOUCHES
  申请人：ENDOTIS PHARMA

  公开号：WO2010029185A1

  公开（公告）日：2010-03-18

  A compound of the following formula or a salt, solvate or formula (I) and a pharmaceutical composition containing said compound. It concerns also its use in the treatment of cancer and/or of pathological angiogenesis and/or in promoting the mobilisation of stem cells, in particular hematopoietic stem cells.

  以下化学式的化合物或盐、溶剂化合物或化学式（I）以及含有该化合物的药物组合物。它还涉及其在治疗癌症和/或病理性血管生成和/或促进干细胞动员，特别是造血干细胞方面的用途。
• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS<br/>[FR] PRO-FRAGMENTS BIORÉVERSIBLES POUR MÉDICAMENTS CONTENANT DE L'AZOTE ET DE L'HYDROXYLE
  申请人：BAIKANG SUZHOU CO LTD

  公开号：WO2015081891A1

  公开（公告）日：2015-06-11

  Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: (I) and pharmaceutical compositions comprising the prodrugs.

  披露了以下公式的促销性质，它们可用于形成含有氮或羟基的药物或药物活性剂的的前药：(I)以及包含这些前药的药物组合物。
• FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, PACLITAXEL, AND ASPIRIN
  申请人：Jacob James N.

  公开号：US20150250844A1

  公开（公告）日：2015-09-10

  The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.

  本发明提供了具有抗炎、镇痛和/或抗癌活性的姜油、鱼油、阿司匹林和抗癌药物（紫杉醇）的新化合物和配方。